Company name



VU University Medical Center Amsterdam

The company

AngioTarget is a Dutch biotech company focusing on the development of a new class of cancer vaccines.

Tumor growth is dependent on the formation of new blood vessels. AngioTarget develops vaccines which specifically target these tumor blood vessels, resulting in starvation of cancer cells. These vaccines are directed against a number of highly specific and proprietary targets of angiogenic endothelial cells.

AngioTarget BV is a spin-off company of the Angiogenesis Laboratory at the department of Medical Oncology, VUMC, Amsterdam. Through a strategic collaboration between VUMC, the Angiogenesis Laboratory and AngioTarget, proprietary targets developed in the Angiogenesis Laboratory are used to generate novel vaccination strategies against the tumor vasculature, for the treatment of cancer.